Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Exosomal SPRY4 from adipogenic BMSCs impairs angiogenesis via the PTPRB/TIE2/PI3K axis in Steroid-induced osteonecrosis of the femoral head.

Xiang D., Zhou Y., Wang H., Chen Y., Bai H., Wang Z.

Animal Study on Chronic Wound, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40660390
DOI
10.1186/s13287-025-04505-0

Abstract (original English)

Steroid-induced osteonecrosis of the femoral head (SONFH) drives irreversible bone collapse, yet current therapies inadequately target the disrupted angiogenic-osteogenic coupling central to its pathogenesis. Although pathological adipocyte hyperplasia is a hallmark of SONFH, the mechanisms by which adipogenic bone marrow mesenchymal stem cells (BMSCs) suppress angiogenesis remain unresolved. Emerging evidence implicates exosomes as mediators of adipose-vascular crosstalk, yet their role in SONFH-associated vasculopathy remains unexplored. Here, we elucidate how adipogenic BMSCs impair angiogenesis in SONFH through exosomal delivery of SPRY4. Adipogenic BMSCs and human umbilical vein endothelial cells (HUVECs) were co-cultured in vitro. RT-PCR was employed to assess the expression of angiogenic genes. Transwell and wound healing assays were conducted to evaluate the migratory capacity of HUVECs. Tube formation assays were performed to investigate HUVEC angiogenesis. RNA sequencing (RNAseq) was utilized to identify potential regulatory factors within exosomes derived from adipogenic BMSCs. The target relationship between SPRY4 and PTPRB was predicted and validated through co-immunoprecipitation and mass spectrometry. Western blotting (WB) was used to confirm the signaling pathway involved in SPRY4-mediated angiogenesis disorders. Hematoxylin and eosin (HE) staining and immunohis

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMesenchymal Stem CellsExosomesAnimalsHuman Umbilical Vein Endothelial CellsPhosphatidylinositol 3-KinasesReceptor, TIE-2Intracellular Signaling Peptides and ProteinsMaleReceptor-Like Protein Tyrosine Phosphatases, Class 3

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research